Kalpress 80 mg film-coated tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Kalpress 80mg film-coated tablets

valsartan

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

1. What Kalpress is and what it is used for
2. What you need to know before taking Kalpress
3. How to take Kalpress
4. Possible side effects
5. How to store Kalpress
6. Contents of the pack and other information

1. What Kalpress is and what it is used for

Kalpress contains the active substance: valsartan and belongs to a class of medicines known as angiotensin II receptor antagonists, which help control high blood pressure. Angiotensin II is a substance in the body that causes blood vessels to narrow, leading to increased blood pressure. Kalpress works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure decreases.

Kalpress 80 mg film-coated tablets can be used for three different conditions:

• to treat high blood pressure in adults and in children and adolescents aged 6 to under 18 years. High blood pressure increases the workload of the heart and arteries. If left untreated, it can damage the blood vessels in the brain, heart, and kidneys, and may lead to stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering blood pressure to normal levels reduces the risk of developing these disorders.
• to treat adult patients after a recent heart attack (myocardial infarction). “Recent” means within 12 hours to 10 days.
• to treat symptomatic heart failure in adult patients. Kalpress is used when a group of medicines called Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) (a medication used to treat heart failure) cannot be used, or may be added to ACE inhibitors when other heart failure medications cannot be used. Symptoms of heart failure include difficulty breathing and swelling of the feet and legs due to fluid retention. This is due to the heart muscle being unable to pump blood strongly enough to supply the body's needs.

2. What you need to know before taking Kalpress

Do not take Kalpress:

• if you are allergic (hypersensitive) to valsartan or to any of the other components of this medicine (listed in section 6).
• if you have severe liver disease.
• if you are more than 3 months pregnant (it is also advisable to avoid Kalpress during the first months of pregnancy – see Pregnancy section).
• if you have diabetes or kidney failure and are being treated with a blood pressure-lowering medicine containing aliskiren.

If any of the above situations apply to you, inform your doctor and do not take Kalpress.

Warnings and precautions:

Consult your doctor

• if you have liver disease.
• if you have severe kidney disease or are undergoing dialysis.
• if you have renal artery stenosis (narrowing of the artery to the kidney).
• if you have recently undergone a kidney transplant (received a new kidney).
• if you have severe heart disease other than heart failure or heart attack.
• if you have previously experienced swelling of the tongue and face due to an allergic reaction called angioedema while taking other medicines (including ACE inhibitors), inform your doctor. If you develop these symptoms while taking Kalpress, stop treatment immediately and never take Kalpress again. See also section 4 “Possible side effects”.
• if you experience abdominal pain, nausea, vomiting, or diarrhoea after taking Kalpress. Your doctor will decide whether to continue treatment. Do not stop taking Kalpress on your own.
• if you are taking medicines that increase blood potassium levels. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines, and heparin. Regular monitoring of blood potassium levels may be necessary.
• if you have aldosteronism, a condition in which the adrenal glands produce too much aldosterone hormone. In this case, taking Kalpress is not recommended.
• if you have lost a large amount of fluid (dehydration) due to diarrhoea, vomiting, or high doses of diuretics (medicines that increase urine output).
• if you are taking any of the following medicines used to treat high blood pressure:
  • an angiotensin-converting enzyme inhibitor (ACEI) (e.g., enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes
  • aliskiren
• if you are being treated with an ACEI together with other specific medicines for heart failure, known as mineralocorticoid receptor antagonists (MRAs) (e.g., spironolactone, eplerenone) or beta-blockers (e.g., metoprolol).

Your doctor may monitor your kidney function, blood pressure, and electrolyte levels (e.g., potassium) at regular intervals.

See also information under the heading “Do not take Kalpress”.

You should inform your doctor if you think you are (or could be) pregnant. Kalpress is not recommended during early pregnancy and must not be taken after 3 months of pregnancy, as it may cause serious harm to your baby if used during this period (see Pregnancy section).

Use of Kalpress with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

The effect of Kalpress treatment may be altered when taken with certain medicines. Your doctor may need to adjust your dose and/or take other precautions, or in some cases discontinue treatment with one of the medicines. This applies to both prescription and over-the-counter medicines, especially:

• other medicines that lower blood pressure, particularly diuretics (medicines that increase urine output), ACE inhibitors (such as enalapril, lisinopril, etc.), or aliskiren (see also information under the headings “Do not take Kalpress” and “Warnings and precautions”).
• medicines that increase potassium levels in the blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines, and heparin.
• certain pain medicines known as non-steroidal anti-inflammatory drugs (NSAIDs).
• some antibiotics (rifampicin group), a medicine used to prevent transplant rejection (cyclosporine), or an antiretroviral medicine used to treat HIV/AIDS infection (ritonavir). These medicines may increase the effect of Kalpress.
• lithium, a medicine used to treat certain psychiatric conditions.

In addition:

• if you are being treated after a heart attack, combination with ACE inhibitors (a medicine used to treat heart attack) is not recommended.
• if you are being treated for heart failure, triple combination therapy with ACE inhibitors and other specific medicines for heart failure, known as mineralocorticoid receptor antagonists (MRAs) (e.g., spironolactone, eplerenone) or beta-blockers (e.g., metoprolol) is not recommended.

Pregnancy and breastfeeding

• Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will usually advise you to stop taking Kalpress before becoming pregnant or as soon as you know you are pregnant, and will recommend an alternative medicine. Kalpress is not recommended during early pregnancy and must not be used from the third month of pregnancy onwards, as it may cause serious harm to your baby when used from this stage.

• Inform your doctor if you are breastfeeding or planning to breastfeed. The use of Kalpress during breastfeeding is not recommended. Your doctor will choose an alternative treatment if you wish to breastfeed, especially if your baby is a newborn or premature.

Driving and using machines

Before driving, operating tools, handling machinery, or engaging in any activity requiring concentration, make sure you know how Kalpress affects you. Like many other medicines used to treat high blood pressure, Kalpress may cause dizziness and may affect your ability to concentrate.

3. How to take Kalpress

To achieve the best results and reduce the risk of adverse effects, always take this medicine exactly as prescribed by your doctor. If in doubt, consult your doctor or pharmacist. People with high blood pressure often do not experience any symptoms and may feel perfectly well. This makes it very important to attend your medical appointments regularly, even if you feel fine.

Adult patients with high blood pressure: The recommended dose is 80 mg once daily. In some cases, your doctor may prescribe higher doses (e.g. 160 mg or 320 mg). Your doctor may also combine Kalpress with another medicine (e.g. a diuretic).

Use in children and adolescents aged 6 to less than 18 years with high blood pressure:

In patients weighing less than 35 kg, the recommended starting dose of valsartan tablets is 40 mg once daily.

In patients weighing 35 kg or more, the recommended starting dose for Kalpress tablets is 80 mg once daily.

In some cases, your doctor may prescribe higher doses (the dose may be increased to 160 mg and up to a maximum of 320 mg).

In children who have difficulty swallowing tablets, administration of the oral solution is recommended.

Adult patients after a recent heart attack: Treatment is usually initiated within 12 hours after a heart attack, typically starting with a low dose of 20 mg twice daily. The 20 mg dose is obtained by dividing the 40 mg tablet. Your doctor will gradually increase this dose over several weeks up to a maximum of 160 mg twice daily. The final dose will depend on your individual tolerance.

Kalpress may be administered together with other treatments for heart attack, and your doctor will decide which treatment is appropriate for you.

Adult patients with heart failure: Treatment is usually initiated with 40 mg twice daily. Your doctor will gradually increase the dose over several weeks up to a maximum of 160 mg twice daily. The final dose will depend on your individual tolerance.

Kalpress may be administered together with other treatments for heart failure, and your doctor will decide which treatment is appropriate for you.

Kalpress may be taken with or without food. Swallow the tablet with a glass of water.

Take Kalpress at approximately the same time each day.

Dosing not covered by available Kalpress presentations

The available Kalpress tablet strengths (80 mg, 160 mg and 320 mg) do not allow administration of the recommended doses for the initial treatment of recent myocardial infarction or heart failure in adults, or for the treatment of arterial hypertension in children weighing < 35 kg. In such cases, alternative formulations of other medicines providing 20 mg or 40 mg of valsartan should be used.

If you take more Kalpress than you should

If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital. You may also call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Kalpress

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose.

Do not take a double dose to make up for a missed dose.

If you stop taking Kalpress

If you discontinue treatment with Kalpress, your condition may worsen. Do not stop taking this medicine unless instructed by your doctor.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Some adverse effects may be serious and may require immediate medical attention:

You may experience symptoms of angioedema (a specific allergic reaction), such as:

• swelling of the face, lips, tongue or throat
• difficulty breathing or swallowing
• hives, itching

If you experience any of these symptoms, stop taking Kalpress and contact your doctor immediately (see also section 2 “Warnings and precautions”).

Other adverse effects include:

Common (may affect up to 1 in 10 people):

• dizziness
• low blood pressure with or without symptoms such as dizziness and fainting upon standing
• reduced kidney function (signs of kidney impairment)

Uncommon (may affect up to 1 in 100 people):

• angioedema (see section “Some symptoms require immediate medical attention”)
• sudden loss of consciousness (syncope)
• sensation of spinning (vertigo)
• marked reduction in kidney function (signs of acute kidney injury)
• muscle spasms, irregular heartbeat (signs of hyperkalemia)
• shortness of breath, difficulty breathing when lying down, swelling of feet or legs (signs of heart failure)
• headache
• cough
• abdominal pain
• nausea
• diarrhea
• fatigue
• weakness

Rare (may affect up to 1 in 10,000 people):

• intestinal angioedema: swelling in the intestine accompanied by symptoms such as abdominal pain, nausea, vomiting and diarrhea.

Frequency not known (cannot be estimated from available data):

• blistering of the skin (sign of bullous dermatitis)
• allergic reactions with skin rash, itching and hives may occur; symptoms of fever, swelling and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms (signs of serum sickness)
• purplish red spots, fever, itching (signs of blood vessel inflammation, also called vasculitis)
• bleeding or bruising more easily than usual (signs of thrombocytopenia)
• muscle pain (myalgia)
• fever, sore throat or mouth ulcers due to infections (symptoms of low white blood cell count, also called neutropenia)
• reduced hemoglobin levels and reduced proportion of red blood cells in the blood (which, in severe cases, may lead to anemia)
• increased potassium levels in the blood (which, in severe cases, may cause muscle spasms and irregular heartbeat)
• elevated liver function test values (indicating possible liver injury), including increased blood bilirubin levels (which, in severe cases, may cause yellowing of the skin and eyes)
• increased blood urea nitrogen and increased serum creatinine levels (which may indicate kidney function abnormalities)
• low sodium levels in the blood (which, in severe cases, may cause fatigue, confusion, muscle fasciculations and/or seizures)

The frequency of certain adverse effects may vary depending on your condition. For example, certain adverse effects such as dizziness and reduced kidney function were observed less frequently in adult patients treated for high blood pressure than in adult patients treated for heart failure or after a recent heart attack.

Adverse effects in children and adolescents are similar to those observed in adults.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines (www.notificaRAM.es). By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Kalpress

• Keep out of the sight and reach of children.
• Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month indicated.
• Do not store above 30°C. Store in the original packaging to protect from moisture.
• Do not use this medicine if the packaging is damaged or shows signs of tampering.
• Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to properly dispose of unused medicines and their containers. This will help protect the environment.

6. Contents of the pack and other information

Composition of Kalpress

• The active substance is valsartan. Each film-coated tablet contains 80 mg of valsartan.
• The other components are microcrystalline cellulose, crospovidone type A, anhydrous colloidal silica, magnesium stearate. The tablet coating contains hypromellose, titanium dioxide (E 171), macrogol 8000, red iron oxide (E 172), yellow iron oxide (E 172).

Appearance of the product and contents of the pack

Kalpress 80 mg film-coated tablets are light red, round, with a score line on one side. They are marked with “D” on one side of the score line and “V” on the other side of the score line, and “NVR” on the opposite face of the tablet. The score line is intended only to facilitate tablet splitting and swallowing, but not to divide the tablet into equal doses.

The tablets are available in blister packs containing 7, 14, 28, 30, 56, 90 or 98 tablets and in calendar blister packs containing 14, 28, 56, 98 and 280 tablets. Single-dose perforated blister packs are also available in sizes of 56x1, 98x1 or 280x1 tablets.

Only certain pack sizes may be marketed.

Marketing Authorization Holder

Novartis Farmacéutica S.A.
Gran Vía de les Corts Catalanes, 764
08013 Barcelona, Spain

Tel: 93-306 42 00

Manufacturer

Novartis Farmacéutica, S.A.
Gran Vía de les Corts Catalanes, 764
08013 Barcelona, Spain

Novartis Farma – Produtos Farmacêuticos, S.A.
Avenida Professor Doutor Cavaco Silva, n.° 10E
Taguspark, Porto Salvo
Oeiras Parish. 2740 255
Portugal

Novartis Sverige AB
Torshamnsgatan 48
164 40 Kista
Sweden

Novartis Farma S.p.A.
Viale Luigi Sturzo 43
20154 Milano (MI)
Italy

Novartis Farma S.p.A.
Via Provinciale, Schito 131
80058 Torre Annunziata (NA)
Italy

For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Laboratorios Gebro Pharma, S.A.
Avenida Tibidabo, 29
08022 Barcelona, Spain
Tel: +34 93 205 86 86

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Date of the most recent review of this leaflet: October 2020

Up-to-date detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/